Tom van Meerten

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron A. Jacobson et al. · New England Journal of Medicine · 2021 · 1.4K citations · Full text

The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20

Jessica L. Teeling, Wendy J.M. Mackus, Luus Wiegman et al. · The Journal of Immunology · 2006 · 599 citations

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten et al. · New England Journal of Medicine · 2023 · 359 citations · Full text

Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells

Keisuke Watanabe, Seitaro Terakura, Anton C. Martens et al. · The Journal of Immunology · 2014 · 280 citations

Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity

Tom van Meerten, Rozemarijn S. van Rijn, Samantha Hol et al. · Clinical Cancer Research · 2006 · 242 citations · Full text